CRTX vs. AIM, SRZN, EVAX, APTO, PLUR, PMCB, SNTI, INKT, ESLA, and QNCX
Should you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include AIM ImmunoTech (AIM), Surrozen (SRZN), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), Pluri (PLUR), PharmaCyte Biotech (PMCB), Senti Biosciences (SNTI), MiNK Therapeutics (INKT), Estrella Immunopharma (ESLA), and Quince Therapeutics (QNCX). These companies are all part of the "medical" sector.
Cortexyme (NASDAQ:CRTX) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
Cortexyme has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -16,123.32%. Cortexyme's return on equity of -70.96% beat AIM ImmunoTech's return on equity.
Cortexyme has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500.
AIM ImmunoTech has higher revenue and earnings than Cortexyme. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.
Cortexyme received 98 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 82.35% of users gave AIM ImmunoTech an outperform vote while only 64.44% of users gave Cortexyme an outperform vote.
63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, AIM ImmunoTech had 4 more articles in the media than Cortexyme. MarketBeat recorded 4 mentions for AIM ImmunoTech and 0 mentions for Cortexyme. Cortexyme's average media sentiment score of 0.00 beat AIM ImmunoTech's score of -1.50 indicating that Cortexyme is being referred to more favorably in the media.
Summary
Cortexyme beats AIM ImmunoTech on 9 of the 14 factors compared between the two stocks.
Get Cortexyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cortexyme Competitors List
Related Companies and Tools
